Clinical trial and real-world evidence of circulating tumor DNA monitoring to predict recurrence in patients with resected colorectal cancer.

ABSTRACT:

Background

Circulating tumor DNA (ctDNA) is a novel biomarker to predict recurrence in colorectal cancer (CRC). However, clinical validation data in underrepresented patient populations like Southeast Asians are lacking.

Materials and methods

In our prospective clinical trial, 92 patients with stage I-IVA CRC and eligible for curative-intent surgery were recruited. Blood samples were collected before surgery, after surgery and during surveillance. ctDNA analysis was carried out using a personalized tumor-informed approach. Performance of ctDNA monitoring was further evaluated in a retrospective analysis of 32 patients who had commercial ctDNA testing.

Results

Before surgery, the ctDNA detection rate was 91.2%, significantly higher than the carcinoembryonic antigen (CE

SUBMITTER: Nguyen HT 

PROVIDER: S-EPMC12836545 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature